Bone Health Technologies Gains $5 Million For Innovative Osteopenia Care

Bone Health Technologies (BHT), a pioneer in health technology, has successfully secured a new funding round of $5 million. This investment was contributed by prominent firms such as Esplanade Ventures, Berkeley Catalyst Fund, and strategic investor Terumo Medical, a global leader in medical technology. The addition of Ella Seitz from Esplanade Ventures and Yushin Yazaki from Terumo as board observers underscores the strategic importance of this funding. This financial boost is timely, aligning with BHT's approach towards receiving de novo FDA clearance for its innovative product aimed at enhancing bone health in postmenopausal women.

The funds are earmarked for the final development phase of Osteoboost, BHT's flagship vibration wearable device. Osteoboost is designed to be worn around the hips and has been clinically validated to safeguard postmenopausal women against the loss of bone strength and density, a common issue associated with menopause and aging. By delivering precision vibration, the device stimulates bone regeneration, effectively reducing the risk of osteopenia progressing to osteoporosis. Impressively, Osteoboost demonstrated a significant slowdown in bone density loss during trials, boasted an adherence rate over 80%, and reported zero serious adverse events.

With over 64 million individuals in the U.S. suffering from osteopenia and osteoporosis, Osteoboost represents a significant advancement as the first non-pharmacological FDA-cleared prescription device targeting this $30 billion market. BHT is currently finalizing manufacturing and distribution arrangements for Osteoboost's market debut expected later this year. Interested patients and healthcare professionals are encouraged to join a notification list to stay updated on the launch.

Laura Yecies, CEO of Bone Health Technologies, expressed gratitude towards the early investors for their faith in BHT's vision and welcomed the new investors who recognized the potential impact of their clinical data on women worldwide. "Bringing a breakthrough, de novo, prescription medical device to market is a challenging road that requires patience and perseverance," Yecies remarked, highlighting the rigorous clinical trial undertaken to validate Osteoboost's efficacy.

Ella Seitz of Esplanade Ventures shared her enthusiasm for BHT's future and the role Osteoboost plays in addressing a critical chronic condition affecting millions of women. "Osteopenia is a serious condition that affects one in six women in North America," Seitz noted, underscoring the substantial improvement Osteoboost could bring to their lives.

Bone Health Technologies, based in Redwood City, leverages science and medical expertise to improve health outcomes for individuals at risk of osteoporosis and related bone fractures. With Osteoboost poised to set a new standard of care for treating postmenopausal osteopenia, BHT continues to receive support from leading investors including Esplanade Ventures, Ambit Health Ventures, Good Growth Capital, Portfolia, Astia Angels, and Golden Seeds. For more details on BHT and Osteoboost, including its full Indications for Use, please visit their website.